NCT04855760View on ClinicalTrials.gov

Safety of REL-1017 for Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

627

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

July 27, 2023

Study Completion Date

July 27, 2023

Conditions
Major Depressive Disorder
Interventions
DRUG

REL-1017

REL-1017 tablet

Trial Locations (9)

10312

Relmada Site, Staten Island

32801

Relmada Site, Orlando

32905

Relmada Site, Palm Bay

33015

Relmada Site, Miami

33175

Relmada Site, Miami

60634

Relmada Site, Chicago

60640

Relmada Site, Chicago

02116

Relmada Site, Boston

02472

Relmada Site, Watertown

All Listed Sponsors
lead

Relmada Therapeutics, Inc.

INDUSTRY

NCT04855760 - Safety of REL-1017 for Major Depressive Disorder | Biotech Hunter | Biotech Hunter